Take home message {#FPar1}
=================

In this *post-hoc* analysis of patients with suspected ischaemic encephalopathy who were enrolled in ICU-ROX, conservative oxygen therapy did not result in a statistically significant decrease in death or unfavourable neurological outcome at day 180 compared with usual oxygen therapy. The potential for clinically important benefit or harm from conservative oxygen therapy in patients with suspected hypoxic ischaemic encephopathy is not excluded by these data.

Introduction {#Sec1}
============

Liberal use of oxygen as occurs with standard management of comatose post-cardiac arrest patients may contribute to secondary brain injury \[[@CR1],[@CR2]\]. For example, exposure to hyperoxaemia worsens brain damage in animal models of cardiac arrest \[[@CR3]\] and hyperoxaemia is independently associated with increased mortality risk in some observational studies in humans \[[@CR4]--[@CR8]\]. However, this association has not been shown in all studies \[[@CR9],[@CR10]\] and one potential concern with conservative use of oxygen therapy is that it might increase exposure to hypoxaemia, which is strongly associated with adverse outcomes in patients who are unconscious after a cardiac arrest \[[@CR9]\]. Only one randomized clinical trial evaluating the effect of different oxygen regimens used in the intensive care unit (ICU) on survival and neurological disability in patients with hypoxic ischaemic encephalopathy has been reported \[[@CR11]\]. This trial reported that conservative oxygen therapy resulted in similar outcomes to liberal oxygen therapy in patients with hypoxic ischaemic encephalopathy but had the insufficient statistical power to detect differences in these outcomes \[[@CR11]\].

We recently reported, in the subgroup of patients with suspected hypoxic ischaemic encephalopathy who were enrolled in the Intensive Care Unit Randomized Trial Comparing Two Approaches to OXygen therapy (ICU-ROX) \[[@CR12]\], that allocation to conservative oxygen therapy was associated with a decreased risk of death and with a numerically lower rate of unfavourable neurological outcomes at 180 days \[[@CR12]\]. It is unclear whether these findings are indicative of true benefit with conservative oxygen therapy or are accounted for by chance baseline imbalances or other confounding factors that may affect outcomes in patients who have suffered a cardiac arrest.

Accordingly, we conducted a post-hoc analysis using data from the 166 patients with suspected hypoxic ischaemic encephalopathy included in ICU-ROX \[[@CR12]\]. Our hypothesis was that, after adjustment for baseline variables that predict outcomes in cardiac arrest patients, use of conservative oxygen therapy would decrease the probability of dying or surviving with an unfavourable neurological outcome at day 180 post-randomization compared with usual oxygen therapy.

Methods {#Sec2}
=======

Trial design {#Sec3}
------------

We conducted a post-hoc analysis in the pre-specified subgroup of patients enrolled in ICU-ROX who were considered to have possible hypoxic ischaemic encephalopathy at the time of enrollment. ICU-ROX was a 1000-participant, multicenter, prospective, parallel-group, randomised clinical trial. The protocol \[[@CR13]\] and primary analysis \[[@CR12]\] have been published previously. ICU-ROX was approved by the ethics committee responsible for each participating institution with approval granted to obtain specific additional data from the medical records of patients with suspected hypoxic ischaemic encephalopathy for this analysis. Written informed consent for enrollment, or consent to continue and to use patient data, was obtained from each patient or from a legal surrogate. Where a patient died before consent to continue could be obtained, data were included if allowed by local regulations and approved by the relevant ethics committee.

Patients {#Sec4}
--------

Patients included in ICU-ROX were mechanically ventilated adults aged ≥ 18 years who were expected to remain mechanically ventilated in the ICU beyond the calendar day after recruitment. Randomization was required within 2 h of invasive mechanical ventilation and/or non-invasive ventilation in an ICU. Otherwise, patients were considered to have missed the enrolment window.

The patients with suspected hypoxic ischaemic encephalopathy included in this analysis constituted a pre-specified subgroup that was defined pre-randomization based on whether this diagnosis was documented in the clinical records. Specific instructions were provided to research coordinators that patients admitted following cardiac arrest, should be defined as being suspected to have hypoxic ischaemic encephalopathy unless there was documentation of the patient obeying commands following the return of spontaneous circulation (ROSC), after the cardiac arrest and prior to the patient being sedated.

For this analysis, we obtained data from the medical records of patients with suspected hypoxic ischaemic encephalopathy that were not initially collected. These data comprised details pertaining to the cardiac arrest including the location of the arrest, whether the arrest was witnessed, whether there was a bystander response, the first monitored rhythm, the cause of the arrest, whether an ST elevation acute myocardial infarction (STEMI) was diagnosed, and the time until sustained ROSC \[[@CR14]\]. We also recorded additional information about comorbidities of particular relevance to patients with cardiovascular disease. Full details of the data collected specifically for this analysis are provided in the Electronic Supplementary Material (ESM).

Randomization and study treatment {#Sec5}
---------------------------------

Patients in ICU-ROX were randomly assigned to conservative oxygen therapy or usual oxygen therapy using a secure Internet-based randomization interface. The allocation sequence was generated by the study statistician using computer-generated random numbers with variable block randomization in a 1:1 ratio stratified by centre.

In both treatment groups, the monitored lower limit alarm for oxygen saturation measured by pulse oximetry (SpO~2~) was set at 90% by default but an alternative lower limit could be specified if clinically indicated. If an arterial blood gas showed a partial pressure of oxygen (PaO~2~) \< 60 mmHg or an unacceptably low arterial oxygen saturation (SaO~2~), the fraction of inspired oxygen (FiO~2~) could be increased, irrespective of SpO~2~.

In patients assigned to conservative oxygen, the FiO~2~ was reduced as much as possible down to a minimum of 0.21 whilst still maintaining the SpO~2~ above the acceptable lower limit. We sought to minimize exposure to an SpO~2~ ≥ 97% and hence minimize the risk of hyperoxaemia in patients assigned to conservative oxygen using an upper SpO~2~ alarm limit set at 97%. This upper limit SpO~2~ alarm was used whenever supplemental oxygen was administered in the ICU.

In patients assigned to usual oxygen, no specific measures limited FiO~2~ or SpO~2~ except that the use of upper alarm limits for SpO~2~ was prohibited and the use of FiO~2~ less than 0.3 during invasive ventilation was discouraged.

Patients received their assigned oxygen therapy strategy until discharge from the ICU or 28 days from randomization, whichever occurred first. Treatment assignment was not disclosed to participants or their families.

For this analysis, we collected information about other treatments of particular relevance to cardiac arrest patients including the drugs that were administered during resuscitation, whether targeted temperature management was used, and if so, what temperature was targeted. We also recorded key neuroprognostic investigations that were performed (ESM).

Outcome measures {#Sec6}
----------------

The primary outcome for this analysis was death or survival with an unfavourable neurological outcome at day 180 defined as an Extended Glasgow Outcome Scale (GOS-E) category of 1--4. This outcome was ascertained by contacting patients or their next of kin.

Secondary outcomes were ICU, hospital, and day 180 mortality, cause-specific mortality, survival time, ICU and hospital length of stay, ventilator-free days, and vasopressor-free days.

Cause-specific mortality was categorized using a previously described method \[[@CR15]\]. Ventilator-free days were defined as the total number of calendar days or part calendar days of unassisted breathing during the first 28 days after randomization, all patients who died by day 28 were assigned zero ventilator-free days \[[@CR16]\]. Vasopressor-free days were defined in an analogous fashion.

Statistical Analysis {#Sec7}
--------------------

The statistical analysis plan for ICU-ROX was reported before enrolment was completed \[[@CR13]\]. Whilst not pre-specified, the analysis reported here was conducted in accordance with the original analysis plan. We chose death or survival with an unfavourable neurological outcome at day 180 as the primary outcome as the most relevant outcome for patients with hypoxic ischaemic encephalopathy. Analyses were conducted on an intention-to-treat basis. We defined the intention-to-treat population as all enrolled patients except those who withdrew consent for use of data. We conducted a post-hoc best/worst analysis to account for missing primary outcome data.

For the primary analysis of death or survival with an unfavourable neurological outcome at day 180, we used an unadjusted Fisher's exact test for equal proportions, and report frequency (percentage) per treatment group with an absolute difference, odds ratio, and associated 95% confidence intervals. Other dichotomous endpoints were analysed in the same fashion. We conducted a sensitivity analysis comparing GOS-E on the ordinal scale. Because there was insufficient proportionality between categories to enable ordinal logical regression, this analysis was undertaken non-parametrically. We compared survival times using log-rank tests and present these as Kaplan--Meier curves and used a Cox proportional-hazards model to calculate hazard ratios for survival. For continuous secondary outcomes, we used a Wilcoxon rank-sum test with differences between medians calculated using quantile regression employing a simplex algorithm with 95% confidence intervals (CI) calculated using the inversion method \[[@CR17]\].

Hierarchical multivariable analyses were performed for all binary outcomes using logistic regression and for survival using a Cox proportional-hazards model. These analyses incorporated adjustment for the independent covariates of age, cardiac arrest location outside the hospital, shockable first monitored rhythm, time to ROSC, whether there was a medical cause for arrest, and whether the patient had a STEMI. A medical cause of cardiac arrest included cases in which the cause of the cardiac arrest was presumed to be cardiac, other medical cause (eg, anaphylaxis, asthma, GI bleed), and cases in which no obvious cause of the cardiac arrest was identified. These analyses were undertaken with patients nested in site and site treated as a random variable. Covariates were pre-specified based on their known associations with neurological outcome in cardiac arrest patients \[[@CR14]\].

Analyses for variables that were measured repeatedly such as time-weighted PaO~2~ were performed using mixed linear modelling (with each patient treated as a random effect) fitting main effect for treatment and time and an interaction between treatment and time to determine if groups behaved differently over time.

Analyses were conducted using SAS statistical software, version 9.4 (SAS Institute). Statistical significance was determined using a two-sided hypothesis test with an alpha of 0.05.

Results {#Sec100}
=======

Patient characteristics {#Sec9}
-----------------------

From September 2015 through May 2018, we enrolled 1000 patients into ICU-ROX from 21 ICUs in Australia and New Zealand. There were 965 patients in the intention-to-treat population. A total of 166 patients were suspected to have hypoxic ischaemic encephalopathy at baseline with 87 (52.4%) of these randomized to conservative oxygen therapy. Data related to neurological outcomes at 6 months were missing for 16 participants (Fig. [1](#Fig1){ref-type="fig"}). The study groups had similar characteristics at baseline (Table [1](#Tab1){ref-type="table"}) and the drugs given during resuscitation were similar (Table [2](#Tab2){ref-type="table"}).Fig. 1Participant flow. *GOS-E* Glasgow Outcome Scale---Extended, *ICU* intensive care unit, *ICU-ROX* intensive care unit randomized trial comparing two approaches to oxygen therapyTable 1Characteristics of the patients at baselineCharacteristicConservative oxygen (*n* = 87)Usual oxygen (*n* = 79)*P* valueAge---year, mean (SD)62.3 ± 14.860.6 ± 16.10.49Male sex---no. (%)66 (75.9%)62 (78.5%)0.69Comorbid conditions---no. (%) Hypertension33 (37.9%)24 (30.4%)0.31 Diabetes24 (27.6%)18 (22.8%)0.48 Ischaemic heart disease18 (20.7%)23 (29.1%)0.21 Asthma or COPD17 (19.5%)15 (19%)0.93 Previous myocardial infarction10 (11.5%)16 (20.3%)0.12 Previous cardiac arrhythmia14 (16.1%)8 (10.1%)0.26 Percutaneous coronary intervention8 (9.2%)10 (12.7%)0.47 Congestive heart failure10 (11.5%)6 (7.6%)0.4 Previous CABG10 (11.5%)5 (6.3%)0.25 Previous TIA or stroke4 (4.6%)7 (8.9%)0.27Cardiac arrest location---no. (%) Emergency department3 (3.4%)6 (7.6%)0.24 Hospital ward5 (5.7%)3 (3.8%)0.56 ICU1 (1.1%)0 (0%)1.00 Operating theatre0 (0%)1 (1.3%)0.48 Other location in hospital1 (1.1%)3 (3.8%)0.35 Home/residence33 (37.9%)32 (40.5%)0.73 Assisted living/nursing home1 (1.1%)2 (2.5%)0.61 Other location (not in hospital)43 (49.4%)32 (40.5%)0.25Witnessed arrest^a^---no. (%)72 (82.8%)61 (77.2%)0.37Bystander response---no. (%)65 (74.7%)56 (70.9%)0.58First monitored rhythm VF, VT, or AED shockable---no. (%)58 (66.7%)46 (58.2%)0.26Response time---mins, mean (SD); range7.3 ± 6.35.0 ± 4.20.01Time to defibrillation---mins, mean (SD)9.7 ± 79.0 ± 5.20.56Time until sustained ROSC---mins, mean (SD); range26.5 ± 17.8 2--8425.4 ± 14.7; 2--660.69Cause of arrest---no. (%) Medical84 (96.6%)71 (89.9%)0.08 Asphyxia3 (3.4%)4 (5.1%)0.71 Drug overdose0 (0%)2 (2.5%)0.23 Drowning0 (0%)1 (1.3%)0.48 Traumatic0 (0%)1 (1.3%)0.48Presence of STEMI---no./*N* (%)23/86 (26.7%)29/77 (37.7%)0.14Physiology^b^ Respiratory rate---breaths per min16.1 ± 3.516.4 ± 4.20.62 SpO~2~---%98 \[96--100\]96 \[95--99\]0.04 PaO~2~---mmHg; median \[IQR\]107 \[86.8--172\]94.5 \[82.5--141\]0.39 PaCO~2~---mmHg49.4 ± 13.847.4 ± 13.40.37Physiological support FIO~2~0.64 ± 0.230.64 ± 0.240.91 PEEP---cmH~2~O; median \[IQR\]5 \[5--10\]8 \[5--10\]0.13 Inotropic/vasopressor support---no. (%)33 (37.9%)34 (43%)0.5Time from ICU admission to randomisation---hours; median \[IQR\]1.25 \[0.62--1.7\]1.1 \[0.7--1.78\]0.84Plus-minus values are expressed as mean ± SD*AED* automated external defibrillator, *COPD* chronic obstructive pulmonary disease, *ICU* intensive care unit, *OR* operating room, *VF* ventricular fibrillation, *VT* ventricular tachycardia, *ROSC* return of spontaneous circulation, *SpO*~*2*~ arterial oxygen saturation on pulse oximetry, *PaO*~*2*~ arterial partial pressure of oxygen, *FiO*~*2*~ fraction of inspired oxygen, *PaCO*~*2*~ arterial partial pressure of carbon dioxide, *PEEP* positive end expiratory pressure^a^A witnessed arrest was defined as one that was seen or heard by another person or was monitored^b^Respiratory rate and SpO~2~ data were available for 86 conservative oxygen patients and 78 usual oxygen patients; PaO~2~ and PaCO~2~ data were available for 79 conservative oxygen patients and 71 usual oxygen patientsTable 2Treatment and prognosticationCharacteristicsConservative oxygen (*n* = 87)Usual oxygen (*n* = 79)*P* value***Pre-randomisation treatment*** Drugs given during resuscitation---no. (%)  Adrenaline60 (69%)60 (75.9%)0.32  Amiodarone24 (27.6%)24 (30.4%)0.69  Vasopressin0 (0%)0 (0%)1.00  None given24 (27.6%)17 (21.5%)0.37  Unknown2 (2.3%)1 (1.3%)1.00***Post-randomisation oxygen therapy*** Proportion of hours SpO~2~ ≥ 97%0.391 (0.254)0.529 (0.257)0.001 Number of hours SpO~2~ ≥ 97%26 \[13--45\]35 \[19--70\]0.05 Proportion of hours SpO~2~ \< 88%0 \[0--0.02\]0 \[0--0.01\]0.37 Number of hours SpO~2~ \< 88%0 \[0--2\]0 \[0--1\]0.4 Proportion of patients with at least one PaO~2~ recording less than 60 mmHg31 (87%)15/79 (19%)0.02 Proportion of patients with at least one PaO~2~ recording greater than 100 mmHg51 (59%)60 (76%)0.02 Proportion of hours FiO~2~ 0.210.37 \[0.08--0.61\]0 \[0--0.12\]\< 0.0001 Number of hours FiO~2~ 0.2125 \[8--43\]0 \[0--6\]\< 0.0001***Other post-randomisation treatment*** Targeted temperature management---no. (%)72 (82.8%)65 (82.3%)0.94  Target 32--34 °C---*n*/*N* (%)3/72 (4.2%)4/65 (6.2%)0.79  Target 36 °C---*n*/*N* (%)51/72 (70.8%)43/65 (66.2%)  Other target---*n*/*N* (%)18/72 (25.0%)18/65 (27.7%)***Neuroprognostic tests performed***^a^***---no. (%)*** Somatosensory evoked potentials (SSEPs)6 (7%)8 (10.1%)0.45 Neurone specific enolase (NSE)0 (0%)0 (0%)1.00 Electroencephalogram (EEG)8 (9.2%)14 (17.7%)0.11 CT brain39 (44.8%)26 (32.9%)0.12 MRI brain5 (5.7%)10 (12.7%)0.12^a^SSEP and NSE data were available for 86 conservative oxygen patients and 78 usual oxygen patients

Oxygenation and process of care measures {#Sec10}
----------------------------------------

Patients allocated to conservative oxygen spent less time in the ICU with an SpO~2~ ≥ 97% (26 h \[interquartile range (IQR) 13--45 vs. 35 h \[IQR 19--70\], absolute difference, − 9 h; 95% CI − 21.4 to 3.4), and more time receiving an FIO~2~ of 0.21 than patients allocated to usual oxygen (25 h \[IQR 8--43\] vs. 0 h \[IQR 0--6\], absolute difference, 25.0 h; 95% CI 18.7--31.1) (Table [2](#Tab2){ref-type="table"}). The time-weighted PaO~2~ over the first 10 days of mechanical ventilation was 84 mmHg (95% CI 78--90 mmHg) for the conservative oxygen therapy group and 88 mmHg (95% CI 82--94 mmHg) for the usual oxygen therapy group; difference − 4 (95% CI − 12.2 to 4.2 mmHg); *P* = 0.33 (Fig. [2](#Fig2){ref-type="fig"}). Highest and lowest daily PaO~2~ during the first 28 mechanical ventilation days are shown in Fig. [2](#Fig2){ref-type="fig"}. Patients allocated to conservative oxygen therapy were significantly more likely to experience episodes of hypoxaemia (PaO~2~ \< 60 mmHg) and significantly less likely to experience episodes of hyperoxaemia (PaO~2~ \> 100 mmHg) than patients allocated to usual oxygen therapy (Table [2](#Tab2){ref-type="table"}). Temperature management strategies used and neuroprognostic tests performed were similar by treatment group (Table [2](#Tab2){ref-type="table"}). The mean FiO~2~ during the first 10 mechanical ventilation days was statistically significantly lower in the conservative oxygen group (Fig S1, ESM). The time-weight daily PaCO~2~ was similar by treatment group (Fig S2, ESM). The mean PEEP values by treatment group are shown in Fig S3 (ESM).Fig. 2PaO~2~ by treatment group while ventilated in ICU\* (**a** time-weighted mean; **b** highest; **c** lowest). \* The number of observations by group on each day is shown on the horizontal axis. The time-weighted mean daily PaO~2~ was calculated from recordings of PaO~2~ taken 6 h while the patient was invasively ventilated in the ICU up until day 10. The highest and lowest PaO~2~ were recorded daily while the patient was invasively ventilated in ICU up until day 28. Data are presented as mean with error bars showing standard error mean. *PaO*~*2*~ arterial oxygen partial pressure, *C* conservative oxygen group, *S* standard (usual) oxygen group

Primary outcome {#Sec11}
---------------

A total of 43 of 78 patients (55.1%) assigned to conservative oxygen therapy and 49 of 72 patients (68.1%) assigned to usual oxygen therapy died or survived with an unfavourable neurological outcome at day 180; absolute difference; − 12.9 percentage points; 95% CI − 28.3 percentage points to 2.5 percentage points; odds ratio 0.58; 95% CI 0.3--1.12; *P* = 0.14; adjusted odds ratio 0.54; 95% CI 0.23--1.26; *P* = 0.15) (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Analyses accounting for missing data are shown in the ESM and indicate even greater imprecision in treatment estimates than the primary analyses. A survival curve focusing on the first 10 days following randomization is shown in Fig. S4 (ESM). In a sensitivity analysis considering the entire ordinal scale, the median GOS-E score was statistically significantly better with conservative oxygen therapy arm compared to usual oxygen therapy 4, IQR 1--7 vs. 1, IQR 1--6; *P* = 0.03.Table 3Primary outcome and key secondary outcomesConservative oxygen (*n* = 87)Usual oxygen (*n* = 79)Estimate^a^ (95% CI)Odds ratioUnadjusted*P* valueAdjusted^b^*P* value Unfavourable neurological outcome at day 180---*n*/*N* (%)43/78 (55.1%)49/72 (68.1%)0.58 (0.3--1.12) 0.100.54 (0.23--1.26)0.15 Day 180 mortality---*n*/*N* (%)37/86 (43%)46/78 (59%)0.53 (0.28--0.98) 0.040.56 (0.25--1.23)0.15 Died in ICU---*n* (%)31 (35.6%)37 (46.8%)0.63 (0.34--1.17) 0.140.68 (0.31--1.48)0.33 Died in hospital---*n* (%)37 (42.5%)43 (54.4%)0.62 (0.34--1.14);0.130.65 (0.3--1.42)0.28Difference in medians (95% CI)*P* valueICU length of stay (days)---median \[IQR\]3.01 \[2.03--5.91\]3 \[1.75--5.67\]0.01 (− 1.21 to 1.23)0.99Hospital length of stay (days)---median \[IQR\]8.72 \[3.89--17.6\]6.49 \[2.31--14.2\]2.23 (− 1.04 to 5.5)0.18Vasopressor-free days---median \[IQR\]23 \[0--26\]0 \[0--25\]23 (12.43--33.57)\< 0.001Duration of vasopressors (days, survivors to day 28)---median \[IQR\]3 \[1--4\], *N* = 512.5 \[1.5--4\]; *N* = 361 (0.03--1.97)0.04Ventilator-free days---median \[IQR\]21.1 \[0--26.1\]0 \[0--26\]21.08 (10.43--31.73)\< 0.001Duration of ventilation (hours, survivors to day 28 only)---median \[IQR\]51 \[27--92\]; *N* = 5145.5 \[23--114\]; *N* = 365.0 (− 27.3 to 37.3)0.52Cause-specific mortality---*n*/*N* (%)*P* value^d^ = 0.87 Arrhythmia8/37 (21.6%)7/46 (15.2%) Brain death3/37 (8.1%)2/46 (4.3%) Brain damage (not brain death)15/37 (40.5%)20/46 (43.5%) Cardiogenic shock9/37 (24.3%)12/46 (26.1%) Distributive shock1/37 (2.7%)1/46 (2.2%) Hypoxic respiratory failure1/37 (2.7%)3/46 (6.5%) Metabolic0/37 (0%)1/46 (2.2%)*IQR* interquartile range, *CI* confidence interval^a^The widths of the confidence intervals for secondary analyses have not been adjusted for multiplicity and the intervals should not be used to infer definite differences between the groups^b^Adjusted for age, cardiac arrest location outside the hospital, shockable first monitored rhythm, time to ROSC, whether there was a medical cause for arrest, and whether the patient had a STEMI. These analyses were undertaken with patients nested in site and site treated as a random variable^c^All differences in medians \[95% CI\] were calculated using quantile regression^d^*P* value for cause-specific mortality calculated using Chi-square testFig. 3Kaplan--Meier estimates of the probability of survival and Glasgow Outcome Scale Extended (GOS-E) categories for patients with suspected hypoxic ischemic encephalopathy\*. \*Adapted from N Engl J Med, ICU-ROX investigators, Conservative Oxygen Therapy During Mechanical Ventilation in the ICU, 382: 989--998 Copyright © 2020 Massachusetts Medical Society. Reprinted with permission. The number of observations in the Kaplan--Meier analysis is shown by treatment group on the horizontal axis. Adjusted hazard ratio, 0.67 (95% CI 0.43--1.03), *P* = 0.20. Adjusted for age, cardiac arrest location outside hospital, shockable first monitored rhythm, time to ROSC, whether there was a medical cause for arrest, and whether the patient had a STEMI. Analysis was undertaken with patients nested in site and site treated as a random variable. *GOS-E* Glasgow Outcome Scale, *ROSC* return of spontaneous circulation, *STEMI* ST elevation acute myocardial infarction

Secondary Outcomes {#Sec12}
------------------

A total of 37 of 86 patients (43%) assigned to conservative oxygen therapy and 46 of 78 (59%) assigned to usual oxygen therapy had died by day 180; absolute difference; − 16 percentage points; 95% CI − 31.1 percentage points to − 0.8 percentage points; odds ratio 0.53; 95% CI 0.28--0.98; *P* = 0.04; adjusted odds ratio 0.56; 95% CI 0.25--1.23; *P* = 0.15. ICU mortality and in-hospital mortality were not significantly different by treatment groups (Table [3](#Tab3){ref-type="table"}). Brain damage was the commonest proximate cause of death and accounted for a similar proportion of deaths in the two treatment groups (Table [3](#Tab3){ref-type="table"}).

ICU and hospital length of stay were similar by treatment group; however, vasopressor-free days and ventilator-free days were statistically significantly higher in the conservative oxygen therapy group. Duration of ventilation among those patients who survived for 28 days or more did not differ significantly by treatment group. However, the duration of vasopressor support among those patients who survived 28 days or more was 1 day longer (95% CI 0.03--1.97) among those allocated to conservative oxygen therapy (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec13}
----------

In this post-hoc analysis of patients with suspected hypoxic ischaemic encephalopathy from the ICU-ROX trial \[[@CR12]\], conservative oxygen therapy was not associated with a statistically significant reduction in death or unfavourable neurological outcomes at day 180 compared with usual oxygen therapy when the GOS-E was dichotomized into favourable and unfavourable outcome categories. While an analysis across the entire ordinal GOS-E favoured conservative oxygen therapy and the point estimate for the treatment effect favoured conservative oxygen therapy in the dichomotised analysis, the 95% confidence interval in this latter analysis was wide. Moreover, in an analysis adjusting for baseline covariates that predict mortality in cardiac arrest patients, the confidence interval was sufficiently wide that it encompassed both clinically important benefit and clinically important harm. Although day 180 mortality was statistically significantly reduced in the conservative group in the originally reported unadjusted analysis \[[@CR12]\], this finding was not robust to the adjustment for differences in baseline covariates reported in the current analysis. There was no statistically significant difference in mortality at other time points and, causes of death did not differ significantly by treatment allocation. We did note statistically significant increases in both ventilator-free days and vasopressor-free days among patients assigned to conservative oxygen therapy.

The largest prior randomized clinical trial evaluating oxygen therapy in patients with suspected hypoxic ischaemic encephalopathy was 2^3^ factorial trial from the COMACARE study group \[[@CR11]\]. In this trial, 123 patients resuscitated from out-of-hospital cardiac arrest were randomized to low-normal or high-normal PaCO~2~ and to normoxia \[arterial oxygen tension (PaO~2~) 75--112.5 mmHg\] or moderate hyperoxia (PaO~2~ 150--187.5 mmHg) and to low-normal or high-normal mean arterial pressure for 36 h in the intensive care unit \[[@CR11]\]. An important difference between the COMACARE trial and ICU-ROX was that the COMACARE trial systematically targeted moderate hyperoxaemia in the control arm. In contrast, in ICU-ROX, the control arm was usual care and no attempt was made to target hyperoxaemia. In ICU-ROX, allocation to conservative oxygen therapy was associated with a statistically significant reduction in the proportion of hours that were spent with an SpO~2~ of ≥ 97%. However, the magnitude of between-group differences in PaO~2~ values in the subgroup of ICU-ROX patients with hypoxic ischaemic encephalopathy was generally smaller than the difference between groups in the COMACARE trial. Despite these differences, our findings are broadly consistent with those of the COMACARE trial where there was no statistically significant effect of oxygen regimens on 30-day mortality rates or the proportion of patients with a good neurological outcome at 6 months but point estimates favoured normoxia. Our data do not preclude the possibility that oxygen regimens that target higher oxygen levels than those used in usual ICU practice are harmful. Patients allocated to conservative oxygen therapy were more likely to be exposed to hypoxaemia. The clinical relevance of the difference in oxygen exposure between groups that we observed, and of the increased frequency of hypoxaemia that we observed in patients allocated to conservative oxygen therapy, can only be established through the conduct of larger randomized clinical trials. If the magnitude of treatment effects on day 180 mortality and unfavourable neurological outcomes suggested by the point estimates observed in this study were confirmed in a larger trial, then the magnitude of separation in oxygen exposure we observed would clearly be important and conservative oxygen therapy would be appropriate to implement despite the associated risk of exposure to hypoxaemia associated with this therapy.

We sought to evaluate whether the difference in day 180 mortality reported in the ICU-ROX trial in patients with suspected with hypoxic ischaemic encephalopathy might be due to chance imbalances between treatment groups. Accordingly, for this study we collected a wide range of data of particular relevance to cardiac arrest patients including arrest details, important co-interventions like temperature management, and details of neuroprognostic tests performed. Although these were generally similar by treatment group, adjustment for pre-specified baseline covariates \[[@CR14]\] resulted in a reduction in the precision of our treatment effect estimates. Our study has a number of limitations. The size of our sample precluded us adjusting for all potentially important baseline variables. We cannot exclude the possibility that usual care patients were sicker as evidenced by their slightly lower average SpO~2~ and slightly more frequent use of adrenaline during resuscitation. It is also possible that there were other imbalances between groups in important variables that we did not measure such as the number of shocks performed, airway control used, or in the use of mechanical compression devices. In addition, differences in outcomes between treatment groups may simply have occurred due to the play of chance. Although the use of neuroprognostic tests was similar by treatment group, the lack of standardization of decisions related to the withdrawal of active treatment, is a potential source of bias in this study. There were 16 patients where data relating to neurological outcomes at 180 days were not available. These data may not be missing at random because patients with better (or worse) outcomes might be harder to contact. We did not collect information related to oxygen delivery such as lactate and central venous oxygen saturation. Although we did not observe a significant increase in hypoxaemia among patients allocated to conservative oxygen therapy, cardiogenic shock and arrhythmias were common causes of death, and the risk of these could potentially be affected by oxygen delivery.

This study includes the largest sample of patients in which oxygen therapy has been evaluated in hypoxic ischaemic encephalopathy in a randomized clinical trial. In this analysis conservative oxygen therapy was not associated with a statistically significant reduction in death or survival with the unfavourable neurological outcome at day 180. The potential for clinically important benefit or harm from conservative oxygen therapy in patients with suspected hypoxic ischaemic encephopathy is not excluded by these data. Our data can be used to inform the design of future trials and indicate that a sample size of 586 would provide 90% power to detect an absolute difference in the proportion of patients with an unfavourable neurological outcome at day 180 of 13 percentage points, based on a control event rate of 68.1%, and using a two-tailed test. Although some clinicians may choose to implement \[[@CR18]\] conservative oxygen therapy in this patient population based on the consistency of animal data \[[@CR3]\], some observational data \[[@CR4]--[@CR8]\], and trends towards benefits from existing randomized controlled trials \[[@CR6],[@CR12]\], further larger trials are needed to provide data that are sufficiently robust to generate clear clinical practice recommendations \[[@CR19]\].
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